Genmab — Februar 2018
-
I tidsskriftet Blood var der i 2017 en artikel, der hed: Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells, som netop understregede et i princippet stort potentiale
-
-
Han har talt..bibob
-
I dag kl. 16..dansk tid
-
Ikke noget epokegørende nyt.
-
Still no breaking news.
-
Morn
utroligt hvad man kan finde af misvisende news https://weeklyregister.com/1-76-eps-expected-for-genmab-a-s-gnmsf/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
